Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.
source https://www.pharmatutor.org/pharma-news/2020/zydus-cadila-receives-final-approval-from-the-usfda-for-cisatracurium-besylate-injection
No comments:
Post a Comment